Propanc Biopharma, Inc.

Investors

Financials

v3.25.2
Consolidated Balance Sheets
Jun. 30, 2025
USD ($)
Jun. 30, 2024
USD ($)
CURRENT ASSETS:    
Cash $ 12,088 $ 21,085
GST tax receivable 5,302 2,950
Prepaid expenses - current portion 8,334,046
Other current assets 1,380 1,406
TOTAL CURRENT ASSETS 8,352,816 25,441
Deferred offering costs 291,773 27,117
Prepaid expenses - long-term portion 10,925,835
Security deposit - related party 1,971 2,008
Operating lease right-of-use assets, net - related party 59,413 17,799
TOTAL ASSETS 19,631,808 72,365
CURRENT LIABILITIES:    
Accounts payable 1,249,596 1,213,335
Accrued expenses and other payables 1,486,550 792,190
Accrued interest 190,795 94,612
Notes payable, net of discount 543,312 204,694
Convertible notes, net of discounts and including put premiums 537,921 399,325
Embedded conversion option liabilities 403,892 133,886
Employee benefit liability 667,901 639,371
TOTAL CURRENT LIABILITIES 5,578,240 3,792,782
NON-CURRENT LIABILITIES:    
Loan payable - long-term - related party, net of discount 105,627 58,642
TOTAL NON-CURRENT LIABILITIES 147,376 58,642
TOTAL LIABILITIES 5,725,616 3,851,424
Commitments and Contingencies (See Note 9)
STOCKHOLDERS’ EQUITY (DEFICIT):    
Common stock, $0.001 par value; 10,000,000,000 shares authorized;11,611,782 and 7,980 shares issued and outstanding as of June 30, 2025 and 2024, respectively 11,612 8
Common stock issuable (7,750 and 0 shares as of June 30, 2025 and 2024, respectively) 8
Additional paid-in capital 138,243,652 61,696,049
Accumulated other comprehensive income 1,318,917 1,269,581
Accumulated deficit (125,621,520) (66,698,220)
Treasury stock ($0.001 share) (46,477) (46,477)
TOTAL STOCKHOLDERS’ EQUITY (DEFICIT) 13,906,192 (3,779,059)
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT) 19,631,808 72,365
Series B Preferred Stock [Member]    
STOCKHOLDERS’ EQUITY (DEFICIT):    
Preferred stock, value
Nonrelated Party [Member]    
CURRENT LIABILITIES:    
Loan payable 65,280 145,091
Related Party [Member]    
CURRENT ASSETS:    
Operating lease right-of-use assets, net - related party 59,413 17,799
CURRENT LIABILITIES:    
Loan payable 415,329 71,629
Operating lease liability - related party, current portion 17,664 19,362
NON-CURRENT LIABILITIES:    
Loan payable - long-term - related party, net of discount 105,627 58,642
Operating lease liability - long-term portion - related party 41,749
Former Director [Member]    
CURRENT LIABILITIES:    
Loan payable 49,528
Due to former director - related party $ 29,759

Source

PDF HTML
10-K Filing
ZIP XLS HTML
XBRL
v3.25.2
Consolidated Statements of Operations and Comprehensive Income (Loss) - USD ($)
 12 Months Ended
Jun. 30, 2025
Jun. 30, 2024
OPERATING EXPENSES    
Administration expenses $ 57,027,850 $ 1,253,797
Occupancy expenses - related party 26,560 34,150
Research and development 223,721 248,102
TOTAL OPERATING EXPENSES 57,278,131 1,536,049
LOSS FROM OPERATIONS (57,278,131) (1,536,049)
OTHER INCOME (EXPENSE)    
Interest expense (563,757) (665,841)
Interest income 9 60
Derivative expense (333,596) (141,012)
Change in fair value of derivative liabilities 212,450 316,537
Gain (loss) on extinguishment of debt, net (871,032) 54,565
Foreign currency transaction gain (loss) (89,243) 22,080
TOTAL OTHER INCOME (EXPENSE), NET (1,645,169) (413,611)
LOSS BEFORE TAXES (58,923,300) (1,949,660)
Tax benefit 129,132
NET LOSS (58,923,300) (1,820,528)
Deemed Dividend (192,960)
NET LOSS AVAILABLE TO COMMON STOCKHOLDERS $ (58,923,300) $ (2,013,488)
BASIC NET LOSS PER SHARE AVAILABLE TO COMMON STOCKHOLDERS $ (14.85) $ (1,420.53)
DILUTED NET LOSS PER SHARE AVAILABLE TO COMMON STOCKHOLDERS $ (14.85) $ (1,420.53)
BASIC WEIGHTED AVERAGE SHARES OUTSTANDING 3,968,176 1,417
DILUTED WEIGHTED AVERAGE SHARES OUTSTANDING 3,968,176 1,417
OTHER COMPREHENSIVE INCOME (LOSS)    
Unrealized foreign currency translation gain (loss) $ 49,336 $ (25,295)
TOTAL OTHER COMPREHENSIVE INCOME (LOSS) 49,336 (25,295)
TOTAL COMPREHENSIVE LOSS $ (58,873,964) $ (2,038,783)

Source

PDF HTML
10-K Filing
ZIP XLS HTML
XBRL
v3.25.2
Consolidated Statements of Cash Flows - USD ($)
 12 Months Ended
Jun. 30, 2025
Jun. 30, 2024
CASH FLOWS FROM OPERATING ACTIVITIES:    
Net loss $ (58,923,300) $ (1,820,528)
Adjustments to Reconcile Net Loss to Net Cash Used in Operating Activities:    
Issuance of common stock for services 51,348,000
Amortization of prepaid stock based expenses 4,621,230
Foreign currency transaction loss (gain) 89,243 (22,080)
Depreciation expense 297
Allowance on refundable advance deposit 120,958
Amortization of debt discounts 303,563 294,005
Amortization of right-of-use assets 20,187 21,359
Change in fair value of derivative liabilities (212,450) (316,537)
Derivative expense 333,596 141,012
Loss (gain) on extinguishment of debt, net 871,032 (54,565)
Non-cash interest expense 5,519 3,832
Accretion of put premium 279,711
Changes in Assets and Liabilities:    
GST receivable (2,405) (71)
Prepaid expenses and other current assets 1,379 4,746
Refundable advance deposit (120,958)
Deferred offering costs (25,000)
Accounts payable 187,732 242,408
Employee benefit liability 40,184 49,196
Accrued expenses and other payables 677,889 209,962
Accrued interest 255,155 78,733
Operating lease liability (21,722) (21,598)
NET CASH USED IN OPERATING ACTIVITIES (405,168) (935,118)
CASH FLOWS FROM FINANCING ACTIVITIES:    
Proceeds from convertible promissory notes, net of original issue discounts and issue costs 222,500 567,050
Repayment of convertible note (8,000) (142,909)
Repayment of notes (122,788)
Proceeds from the sale of common stock 23,057
Proceeds from note payable 320,000 190,000
Proceeds from loans payable 79,811
Proceeds from loans payable - related parties 343,700 224,885
Deferred offering costs (264,656)
NET CASH PROVIDED BY FINANCING ACTIVITIES 490,756 941,894
Effect of exchange rate changes on cash (94,585) 4,262
NET INCREASE (DECREASE) IN CASH (8,997) 11,038
CASH AT BEGINNING OF YEAR 21,085 10,047
CASH AT END OF YEAR 12,088 21,085
Cash paid during the year:    
Interest 30,715 9,491
Income Tax
Supplemental Disclosure of Non-Cash Investing and Financing Activities    
Reduction of put premium related to conversions of convertible notes 10,229 246,254
Conversion of convertible notes and accrued interest to common stock 79,686 560,483
Settlement of accounts payable for shares of common stock 129,354
Settlement of loans to former director for shares of common stock 74,395
Settlement of loans payable including accrued interest for shares of common stock 86,248
Debt discounts related to derivative liability 222,500 150,000
Operating lease right-of-use asset and operating lease liability pursuant to ASC 842 62,126
Relative fair value of warrant granted in connection with a loan payable - related party 141,084
Issuance of common stock for prepaid services (net of amortized portion) 19,259,880
Deemed dividend upon alternate cashless exercise of warrants $ 192,960

Source

PDF HTML
10-K Filing
ZIP XLS HTML
XBRL

Sign up for email alerts

Be the first to receive breaking news

Sign up today